US patent bill has House backing
This article was originally published in Clinica
Executive Summary
A bill introduced by Californian Republican Dana Rohrabacher would ensure that the General Agreement on Tariffs & Trade does not adversely affect US patent holders. GATT calculates patent life as 20 years from the date of application, US patents now expire 17 years after the date of issuance. The US Patent Office estimates patents are issued, on average, 19.5 months after application but industry is concerned about those which fall outside the average.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.